首页> 美国卫生研究院文献>Cytotechnology >Chemical genomics: massively parallel technologies for rapid lead identification and target validation
【2h】

Chemical genomics: massively parallel technologies for rapid lead identification and target validation

机译:化学基因组学:大规模并行技术可快速识别铅和验证靶标

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Chemical genomics is a new research paradigm with importantapplications in drug discovery. It links genomic targets withsmall-molecule chemistries thereby allowing for efficient targetvalidation and lead compound identification. ACADIA'schemical-genomics platform consists of a large and diverse small-moleculelibrary (800,000), a reference drug library (2,000), druggablegenomic targets (>300) and a cell-based functional assaytechnology (R-SATTM; Receptor Selection and AmplificationTechnology) that allows for ultra-high throughput screening(>500,000 data points/week) as well as high throughputpharmacology and profiling over a wide range of targets. Twoexamples are presented that illustrate the success of ourchemical-genomics approach: (i) The validation of inverse agonismat serotonin 5-HT2A receptors as an antipsychotic mechanismand the subsequent discovery of potent and selectively acting 5-HT2A inverse agonists, currently in preclinical development,and (ii) the discovery of the first ectopically binding subtype-selective muscarinic m1 agonist.
机译:化学基因组学是一种新的研究范例,在药物发现中具有重要的应用。它将基因组靶标与小分子化学联系起来,从而实现有效的靶标验证和前导化合物鉴定。 ACADIA的化学基因组学平台包括一个大型多样的小分子数据库(800,000),参考药物库(2,000),药物基因组靶标(> 300)和基于细胞的功能测定技术(R-SAT TM ;受体选择和扩增技术)可用于超高通量筛选(> 500,000个数据点/周)以及高通量药理学和针对广泛靶标的分析。提出了两个例子来说明我们的化学基因组学方法的成功:(i)验证逆神经素5-羟色胺5-HT2A受体作为抗精神病机制,以及随后发现有效且选择性作用的5-HT2A反向激动剂(目前正在临床前开发中),以及(ii)发现第一个异位结合的亚型选择性毒蕈碱型m1激动剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号